LabCorp completes $1.2B Chiltern buy

Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International.

Chiltern is slated to fold into the company’s Covance drug development business, which conducts clinical trials for drugmakers.

Get the full story at our sister site, Drug Delivery Business News.

The post LabCorp completes $1.2B Chiltern buy appeared first on MassDevice.

from MassDevice http://ift.tt/2eLz8SF